Drug Profile
W 0101
Alternative Names: W-0101Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 28 Aug 2019 Pierre Fabre intends to launch W 0101 in 2028 (Pierre Fabre pipeline, August 2019)
- 28 Aug 2019 Pierre Fabre plans a phase IIa trial in Solid tumours in March 2020 (Pierre Fabre pipeline, August 2019)
- 21 Apr 2018 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)